Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov 27;187(24):6981-6993.e23.
doi: 10.1016/j.cell.2024.09.039. Epub 2024 Oct 21.

P-stalk ribosomes act as master regulators of cytokine-mediated processes

Affiliations

P-stalk ribosomes act as master regulators of cytokine-mediated processes

Anna Dopler et al. Cell. .

Abstract

Inflammatory cytokines are pivotal to immune responses. Upon cytokine exposure, cells enter an "alert state" that enhances their visibility to the immune system. Here, we identified an alert-state subpopulation of ribosomes defined by the presence of the P-stalk. We show that P-stalk ribosomes (PSRs) are formed in response to cytokines linked to tumor immunity, and this is at least partially mediated by P-stalk phosphorylation. PSRs are involved in the preferential translation of mRNAs vital for the cytokine response via the more efficient translation of transmembrane domains of receptor molecules involved in cytokine-mediated processes. Importantly, loss of the PSR inhibits CD8+ T cell recognition and killing, and inhibitory cytokines like transforming growth factor β (TGF-β) hinder PSR formation, suggesting that the PSR is a central regulatory hub upon which multiple signals converge. Thus, the PSR is an essential mediator of the cellular rewiring that occurs following cytokine exposure via the translational regulation of this process.

Keywords: P-stalk; T cells; cytokines; melanoma; ribosome.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests The authors declare no competing interests.

References

    1. Hanahan D (2022). Hallmarks of Cancer: New Dimensions. Cancer Discov. 12, 31–46. 10.1158/2159-8290.cd-21-1059. - DOI - PubMed
    1. Waldman AD, Fritz JM, and Lenardo MJ (2020). A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat. Rev. Immunol. 20, 651–668. 10.1038/s41577-020-0306-5. - DOI - PMC - PubMed
    1. Zhou X, Ni Y, Liang X, Lin Y, An B, He X, and Zhao X (2022). Mechanisms of tumor resistance to immune checkpoint blockade and combination strategies to overcome resistance. Front. Immunol. 13, 915094. 10.3389/fimmu.2022.915094. - DOI - PMC - PubMed
    1. Bagaev A, Kotlov N, Nomie K, Svekolkin V, Gafurov A, Isaeva O, Osokin N, Kozlov I, Frenkel F, Gancharova O, et al. (2021). Conserved pan-cancer microenvironment subtypes predict response to immunotherapy. Cancer Cell 39, 845–865.e7. 10.1016/j.ccell.2021.04.014. - DOI - PubMed
    1. Tray N, Weber JS, and Adams S (2018). Predictive Biomarkers for Checkpoint Immunotherapy: Current Status and Challenges for Clinical Application. Cancer Immunol. Res. 6, 1122–1128. 10.1158/2326-6066.cir-18-0214. - DOI - PubMed